News from Creabilis SA A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

29 Jul, 2013, 04:57 ET Creabilis Appoints Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board

Creabilis SA, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces that it has appointed Professor...


10 May, 2013, 03:00 ET Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327

Clinically and Statistically Significant Reduction of Chronic Pruritus (Itch) Seen in Psoriasis Patients Creabilis, a late stage European...


23 Apr, 2013, 06:39 ET Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE 'Topical-by-Design' Technology

Creabilis SA, a late clinical stage European biotechnology company specialising in the development of treatments in dermatology, for inflammation...


28 Feb, 2013, 04:37 ET Creabilis Appoints Catherine Moukheibir to its Board of Directors

Creabilis SA, a late clinical stage European biotechnology company specialising in the development of treatments in dermatology, inflammation and...


05 Nov, 2012, 04:47 ET Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award

£1.42m Funding Will Drive Development of New Treatment for Atopic Dermatitis Creabilis SA, a European biotechnology company specialising in...


03 May, 2012, 04:00 ET Creabilis Appoints Dr Simon Russell as Chief Business Officer

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, announces...


29 Feb, 2012, 04:00 ET Creabilis Announces Start of Phase IIb Trial of TrkA Kinase Inhibitor CT327 in Psoriasis

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today...


04 Oct, 2011, 03:00 ET Creabilis Raises €15M ($20M) in Series B Fundraising Round

Funds to Advance Development of Creabilis' First-in-Class Products Creabilis SA, a clinical stage European biotechnology company addressing unmet...


18 Aug, 2011, 04:00 ET Creabilis Expands Senior Management Team

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, announced...


04 Aug, 2011, 05:12 ET Creabilis Appoints Dr David Roblin as Chief Medical Officer

  Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain,...


10 Mar, 2011, 03:59 ET Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from...


15 Dec, 2010, 04:25 ET Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Atopic Dermatitis

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results in...


29 Sep, 2010, 04:28 ET Creabilis Appoints Dr. Eliot Forster as its New Chief Executive Officer

Creabilis SA, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, today...


15 Sep, 2010, 03:59 ET Creabilis Appoints George F. Horner III as its Chairman

Creabilis SA, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, today...